Sugi Predict

Sugi Predict / Compounds / SCHEMBL4949039

SCHEMBL4949039

SCHEMBL4949039

O=C(NCCO)C(O)C(O)C(O)C(O)CO

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ ALDH1A1 P00352 1/20 0.65
▸ MAPT P10636 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ PDE4A P27815 1/20 0.52
▸ LMNA P02545 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.42
▸ SLCO1B1 Q9Y6L6 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ TSHR P16473 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ PTGS1 P23219 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ ANPEP P15144 1/20 0.33
▸ DNPEP Q9ULA0 1/20 0.33
▸ GPBAR1 Q8TDU6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8018571 1.00 USP2 (0.65) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL8939170 0.92 PDE4A (0.56) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL16316374 0.92 PDE4A (0.56) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL1569115 0.89 USP2 (0.81) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL12346228 0.89 USP2 (0.81) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL22233098 0.89 USP2 (0.50) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL9323008 0.88 PDE4A (0.52) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL8991473 0.88 PDE4A (0.52) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL9321565 0.88 PDE4A (0.52) USP2MEN1ALDH1A1MAPTKMT2A
SCHEMBL25014974 0.86 PDE4A (0.50) USP2MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025056372-A1 COMPOSITIONS GIVAUDAN SA (CH) 2025-03-20 — — WO claimed
EP-2941408-A1 CERAMIC PRECURSOR BATCH COMPOSITIONS FOR INCREASED TONSET USING ORGANIC ADDITIVE HETEROATOM POLYOLS Corning Incorporated (US) 2015-11-11 — — EP claimed
WO-2014070537-A1 CERAMIC PRECURSOR BATCH COMPOSITIONS FOR INCREASED TONSET USING ORGANIC ADDITIVE HETEROATOM POLYOLS CORNING INCORPORATED (US) 2014-05-08 — — WO claimed
US-20140117594-A1 Ceramic Precursor Batch Compositions For Increased Tonset Using Organic Additive Heteroatom Polyols CORNING INCORPORATED (US) 2014-05-01 — — US claimed
CN-101493447-B Method for inspecting catalytic capability of glucose oxidation bacterium LUNAN PHARM GROUP CORP 2010-08-18 — — CN claimed
CN-101493447-A Method for inspecting catalytic capability of glucose oxidation bacterium LUNAN PHARM GROUP CORP (CN) 2009-07-29 — — CN claimed
WO-2025056372-A1 COMPOSITIONS GIVAUDAN SA (CH) 2025-03-20 — — WO disclosed
US-20240277012-A1 DUPLICATE BEVERAGE WANG JIE (US) 2024-08-22 — — US disclosed
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 — — US disclosed
CN-114516831-B Preparation method of miglitol 浙江奥翔药业股份有限公司 2024-03-08 — — CN disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 — — US disclosed
US-11517036-B2 Flavor modifiers for meat analog products GIVAUDAN SA (CH) 2022-12-06 — — US disclosed
EP-3368542-B1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2022-06-22 — — EP disclosed
WO-2014070537-A1 CERAMIC PRECURSOR BATCH COMPOSITIONS FOR INCREASED TONSET USING ORGANIC ADDITIVE HETEROATOM POLYOLS CORNING INCORPORATED (US) 2014-05-08 — — WO disclosed
US-20140117594-A1 Ceramic Precursor Batch Compositions For Increased Tonset Using Organic Additive Heteroatom Polyols CORNING INCORPORATED (US) 2014-05-01 — — US disclosed
US-20140117594-A1 Ceramic Precursor Batch Compositions For Increased Tonset Using Organic Additive Heteroatom Polyols CORNING INCORPORATED (US) 2014-05-01 — — US disclosed
US-20130281387-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2013-10-24 — — US disclosed
WO-2012054528-A2 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ELCELYX THERAPEUTICS, INC. (US) 2012-04-26 — — WO disclosed
CN-101493447-B Method for inspecting catalytic capability of glucose oxidation bacterium LUNAN PHARM GROUP CORP 2010-08-18 — — CN disclosed
CN-101493447-A Method for inspecting catalytic capability of glucose oxidation bacterium LUNAN PHARM GROUP CORP (CN) 2009-07-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 USP2 4693/4885MEN1 2644/4885ALDH1A1 978/4885
US-20130281387-A1 Chemosensory Receptor Ligand-Based Therapies GPR119, TAS1R2, TAS2R1 USP2 2583/4885MEN1 3628/4885ALDH1A1 796/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 USP2 4693/4885MEN1 2644/4885ALDH1A1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.